Access to anti-retroviral drugs, female in Oman

Oman: Access to anti-retroviral drugs, female was 76.0% in 2024. ◆ Volatile

Latest (2024)
76.0%
Change on year
up 2.7%
World rank
64th
of 141 countries
All-time high
76.0%
in 2024
All-time low
9.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Oman, 2000–2024

0204060802000201220242000: 9 %2001: 11 %2002: 12 %2003: 14 %2004: 15 %2005: 17 %2006: 18 %2007: 25 %2008: 28 %2009: 34 %2010: 42 %2011: 48 %2012: 47 %2013: 53 %2014: 52 %2015: 54 %2016: 59 %2017: 63 %2018: 66 %2019: 71 %2020: 65 %2021: 70 %2022: 70 %2023: 74 %2024: 76 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Oman is 76.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 2.7% on the previous year and up 46.2% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Oman peaked at 76.0% in 2024 and was at its lowest, 9.0%, in 2000.

Oman ranks 64th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Oman, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Oman, 2000 to 2024.
Year % Change
2000 9.0%
2001 11.0% +22.2%
2002 12.0% +9.1%
2003 14.0% +16.7%
2004 15.0% +7.1%
2005 17.0% +13.3%
2006 18.0% +5.9%
2007 25.0% +38.9%
2008 28.0% +12.0%
2009 34.0% +21.4%
2010 42.0% +23.5%
2011 48.0% +14.3%
2012 47.0% -2.1%
2013 53.0% +12.8%
2014 52.0% -1.9%
2015 54.0% +3.8%
2016 59.0% +9.3%
2017 63.0% +6.8%
2018 66.0% +4.8%
2019 71.0% +7.6%
2020 65.0% -8.5%
2021 70.0% +7.7%
2022 70.0% +0.0%
2023 74.0% +5.7%
2024 76.0% +2.7%

Averages by decade

DecadeAverage LowestHighest Years
2000s 18.3% 9.0% 34.0% 10
2010s 55.5% 42.0% 71.0% 10
2020s 71.0% 65.0% 76.0% 5

Countries ranked near Oman

  1. 63 Colombia 77.0% compare
  2. 64 Bahamas 76.0% compare
  3. 64 Honduras 76.0% compare
  4. 67 Ecuador 75.0% compare
  5. 67 Guyana 75.0% compare

See the full ranking of 160 places →

More gender data for Oman

All data for Oman →

Frequently asked questions

What is access to anti-retroviral drugs, female in Oman?
Access to anti-retroviral drugs, female in Oman was 76.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Oman?
The highest recorded value was 76.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Oman?
The lowest recorded value was 9.0% in 2000.
How does Oman rank for access to anti-retroviral drugs, female?
Oman ranks 64th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Oman?
Over the last ten years it is up 46.2%. The long-run trend across the full record is volatile.
Where does this Oman data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Oman. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/oman/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/oman/">Access to anti-retroviral drugs, female in Oman</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.